ImmunityBio, Inc. — CureCurrent

How to interpret these research links

Connected source records

The exact organization name ImmunityBio, Inc. appears in 18 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials18

Recruiting shown2

Roles2

SourceClinicalTrials.gov

Clinical trials

18 shown

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InNCT06745908 · lead sponsor · 2025-10-01

RECRUITING

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLCNCT07524257 · lead sponsor · 2026-05-29

WITHDRAWN

Immunotherapy Before and After SurgeryNCT06765902 · lead sponsor · 2025-12-15

WITHDRAWN

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.NCT06765954 · lead sponsor · 2025-12-01

WITHDRAWN

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior TherapiesNCT04927884 · lead sponsor · 2021-09-08

TERMINATED

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667 · lead sponsor · 2018-12-11

ACTIVE_NOT_RECRUITING

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineNCT03554109 · lead sponsor · 2018-09-01

WITHDRAWN

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerNCT03574649 · lead sponsor · 2018-06-01

WITHDRAWN

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerNCT03520686 · lead sponsor · 2018-05-18

TERMINATED

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.NCT03387085 · lead sponsor · 2018-03-19

TERMINATED

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsNCT03169738 · lead sponsor · 2018-02-01

WITHDRAWN

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyNCT03175666 · lead sponsor · 2017-12-01

WITHDRAWN

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung CancerNCT02200757 · lead sponsor · 2015-04-20

COMPLETED

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's SarcomaNCT02029430 · lead sponsor · 2014-04-03

COMPLETED

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung CancerNCT07355205 · collaborator · 2026-07-07

RECRUITING

Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate CancerNCT07756593 · collaborator · 2026-11-30

NOT_YET_RECRUITING

Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLCNCT05007769 · collaborator · 2021-10-31

WITHDRAWN

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment InterruptionNCT04340596 · collaborator · 2021-05-21

ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

23 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing ImmunityBio, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

cyclophosphamide6

paclitaxel protein-bound5

cisplatin4

fluorouracil4

leucovorin4

capecitabine3

avelumab2

docetaxel2

Sponsor roles

lead sponsor14

collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.